FOXP3 and cancer: Furthermore, as PD-1/PD-L1 and CTLA4 inhibitors have been extensively evaluated clinically in patients with many cancer types, combinations of FoxP3 regulators and ICIs may be possible to test where ICIs do not work optimally.